Literature DB >> 9270509

A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent.

D L Greer1, J Weiss, D A Rodriguez, A A Hebert, J M Swinehart.   

Abstract

BACKGROUND: Tinea corporis treatment usually requires topical application of an antifungal agent for 2 to 3 weeks.
OBJECTIVE: We evaluated short-term treatment of tinea corporis with butenafine hydrochloride, a new benzylamine with in vitro fungicidal activity.
METHODS: Patients (n = 78) were randomly selected to apply butenafine or its cream vehicle alone once daily for 14 days and were periodically assessed until day 42.
RESULTS: Butenafine recipients had significantly higher rates of mycologic cure beginning at day 7 (64% vs 9%) with continued improvements through day 42 (88% vs 17%). They also had higher rates of effective treatment (mycologic cure and 90% to 100% symptom improvement) at day 7 (33% vs 0%) with increasing rates through day 42 (81% vs 14%).
CONCLUSION: Butenafine provides rapid and persistent antifungal activity and symptom relief in patients with tinea corporis. Significant effects were observed within 7 days of therapy initiation, and increasing effectiveness was observed 4 weeks after therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9270509     DOI: 10.1016/s0190-9622(97)80130-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 2.  Butenafine.

Authors:  W McNeely; C M Spencer
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

3.  Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities.

Authors:  Ana María Garzón Porras; Bruna Silva Terra; Taniris Cafiero Braga; Thais Furtado Ferreira Magalhães; Cleide Viviane Buzanello Martins; Danielle Letícia da Silva; Ludmila Matos Baltazar; Ludmila Ferreira Gouveia; Gustavo José Cota de Freitas; Daniel Assis Santos; Maria Aparecida Resende-Stoianoff; Beth Burgwyn Fuchs; Eleftherios Mylonakis; Rossimiriam Pereira de Freitas; Ângelo de Fátima
Journal:  J Adv Res       Date:  2018-06-21       Impact factor: 10.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.